Stockscreener 앱 받기
127.88
3.26%
4.04
시간 외 거래:
127.46
-0.42
-0.33%
전일 마감가:
$123.84
열려 있는:
$125.25
하루 거래량:
19.53M
Relative Volume:
2.86
시가총액:
$158.77B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
17.40
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
+3.33%
1개월 성능:
-4.37%
6개월 성능:
+2.55%
1년 성능:
+18.83%
1일 변동 폭
$125.00
$128.70
1주일 범위
$123.00
$128.70
52주 변동 폭
$106.84
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
127.88 | 158.77B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Gilead Sciences launches Trodelvy in TNBC, shares hold near $128 - Ad-hoc-news.de
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC - Insider Monkey
Price to sales forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Enterprise value to revenue forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval - Ad-hoc-news.de
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative? - Yahoo Finance
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe - Yahoo Finance
Price to book forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Price to earnings forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Inc (GILD) Shares Surge 3.3% -- What GF Score of 75 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences, Inc. Actuals & Estimates (VIE:GILD) - TradingView
Gilead Sciences, Inc. Actuals & Estimates (LSX:885823) - TradingView
Gilead Sciences, Inc. Actuals & Estimates (NASDAQ:GILD) - TradingView
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results - Insider Monkey
Gilead Sciences consensus stays robust, analysts stick to Moderate Buy rating - Ad-hoc-news.de
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh - TradingView
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know - sharewise.com
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga
Could Chemotherapy Soon Be Optional? AstraZeneca and Gilead Drugs Show Promise for Breast Cancer Patients - Health and Me
Gilead Sciences updates oncology pipeline, shares steady on NASDAQ - Ad-hoc-news.de
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use - Yahoo Finance
Gilead Sciences secures key FDA cancer approval, shares trade near recent highs - Ad-hoc-news.de
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer - BioSpace
Photo gallery, Gilead Sciences v Pain Relief Rx et al - Partnership for Safe Medicines
OP Asset Management Ltd Acquires Shares of 256,653 Gilead Sciences, Inc. $GILD - MarketBeat
New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News
Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer - marketscreener.com
GILD Receives FDA Approval for Trodelvy in Triple-Negative Breas - GuruFocus
FDA approves Gilead’s Trodelvy for first-line breast cancer By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC - Yahoo Finance Singapore
Astellas Padcev and Gilead's Trodelvy grab key EU approvals - pharmaphorum
5 Set-It-and-Forget-It Stocks to Buy Right Now - Insider Monkey
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Trade Ideas — BCBA:GILD.CI - TradingView
Gilead Sciences highlights ongoing commitment to Pride, inclusion in community and workplace - ABC7 Bay Area
Gilead receives EU nod for Trodelvy in first-line metastatic triple-negative breast cancer - grafa.com
EC approves Trodelvy as a first-line treatment for TNBC - The Pharma Letter
GILD Gains EU Approval for Trodelvy in Treating Triple-Negative Breast Cancer - GuruFocus
Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha
Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com
Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment - marketscreener.com
as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors - Business Wire
Gilead Sciences draws Cantor support, shares sit below $155 target - AD HOC NEWS
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com UK
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 - Investing.com UK
Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares - AD HOC NEWS
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Moomoo
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.62%
자본화:
|
볼륨(24시간):